PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibition - PubMed
4 hours ago
- #EZH2 inhibition
- #PRC2
- #SCLC
- PRC2 loss impairs small cell lung cancer (SCLC) tumorigenesis.
- Conditional deletion of Eed, a core component of PRC2, prevents tumor formation in SCLC.
- Enzymatic inhibition of EZH2 (a PRC2 component) does not affect tumor growth but alters the PRC2 interactome.
- Prolonged EZH2 inhibition sensitizes neuroendocrine cancer cells to G9a/GLP inhibition.
- Combination of EZH2 and G9a/GLP inhibitors triggers an oxidative stress response, reversible by antioxidants.
- The study highlights PRC2's structural role in SCLC and identifies potential drug combinations to enhance EZH2 inhibitor efficacy.